AU2002337713A1 - Pharmaceutical compositions and methods for treating cancer - Google Patents

Pharmaceutical compositions and methods for treating cancer

Info

Publication number
AU2002337713A1
AU2002337713A1 AU2002337713A AU2002337713A AU2002337713A1 AU 2002337713 A1 AU2002337713 A1 AU 2002337713A1 AU 2002337713 A AU2002337713 A AU 2002337713A AU 2002337713 A AU2002337713 A AU 2002337713A AU 2002337713 A1 AU2002337713 A1 AU 2002337713A1
Authority
AU
Australia
Prior art keywords
methods
pharmaceutical compositions
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002337713A
Other languages
English (en)
Inventor
James W. Emlen
Brent F. G. Treiger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of AU2002337713A1 publication Critical patent/AU2002337713A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2002337713A 2001-09-26 2002-09-26 Pharmaceutical compositions and methods for treating cancer Abandoned AU2002337713A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32524601P 2001-09-26 2001-09-26
US60/325,246 2001-09-26
PCT/US2002/030621 WO2003026581A2 (en) 2001-09-26 2002-09-26 Pharmaceutical compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
AU2002337713A1 true AU2002337713A1 (en) 2003-04-07

Family

ID=23267053

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002337713A Abandoned AU2002337713A1 (en) 2001-09-26 2002-09-26 Pharmaceutical compositions and methods for treating cancer

Country Status (5)

Country Link
US (1) US20040191218A1 (cg-RX-API-DMAC10.html)
EP (1) EP1435965A4 (cg-RX-API-DMAC10.html)
JP (1) JP2005508323A (cg-RX-API-DMAC10.html)
AU (1) AU2002337713A1 (cg-RX-API-DMAC10.html)
WO (1) WO2003026581A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ589276A (en) * 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
NZ575388A (en) * 2006-10-06 2012-03-30 Bn Immunotherapeutics Inc Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer
RU2346692C2 (ru) * 2007-03-29 2009-02-20 Ефаг АО Применение 9-оксоакридин-10-уксусной кислоты, ее солей и сложных эфиров в комбинированной терапии рака яичников, способ лечения и наборы
HK1242996A1 (zh) * 2014-11-14 2018-07-06 豪夫迈．罗氏有限公司 预测对vegf拮抗剂的响应
CN105726475B (zh) * 2016-04-12 2018-05-04 青岛市妇女儿童医院 一种治疗晚期卵巢癌的注射液及其制备方法
CN108143714A (zh) * 2016-04-12 2018-06-12 夏建明 一种用于治疗晚期卵巢癌的注射液及其制备方法
CN119698551A (zh) * 2022-08-10 2025-03-25 学校法人日本大学 试样的检查方法、妇科癌症及其癌前病变的检查试剂盒及医药品
JP7716691B2 (ja) * 2022-08-10 2025-08-01 学校法人日本大学 試料の検査方法、婦人科癌及びその前癌病変の検査キット及び医薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH605550A5 (cg-RX-API-DMAC10.html) * 1972-06-08 1978-09-29 Research Corp
US4657927A (en) * 1978-05-04 1987-04-14 Research Corporation Malonato platinum compounds
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5440056A (en) * 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.

Also Published As

Publication number Publication date
EP1435965A2 (en) 2004-07-14
JP2005508323A (ja) 2005-03-31
WO2003026581A3 (en) 2004-03-04
US20040191218A1 (en) 2004-09-30
EP1435965A4 (en) 2005-09-21
WO2003026581A2 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
AU2003230750A1 (en) Compositions and methods for treating cancer
EP2671581B8 (en) Compositions and methods for treating cancer
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2002324914A1 (en) Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
AU2002329022A1 (en) Method and pharmaceutical composition for treating inflammation
AU2003225535A1 (en) Methods and compositions for treating cancer
AU2002328952A1 (en) Irinotecan for treatment of cancer
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
AU2002364708A1 (en) Novel compositions and methods for cancer
WO2004058153A9 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
IL145397A0 (en) Compositions and methods for treatment of cancer
EP1469769A4 (en) NEW COMPOSITIONS AND METHODS AGAINST CANCER
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
AU2002311859A1 (en) Compositions and methods for treating colorectal polyps and cancer
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU2002308642A1 (en) Methods for treating cancer
AU2002349268A1 (en) Medicine for preventing and treating bromidrosis
AU2002337943A1 (en) Novel compositions and methods for cancer
AU2001278738A1 (en) Medicinal compositions for preventing and treating cancer
AUPR644301A0 (en) Method and composition for treatment of cancer
EP1469870A4 (en) NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
AU2003298708A1 (en) GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
AU2001238179A1 (en) Method and compositions for treating hepatocellular cancer
AU2002305138A1 (en) Methods and materials for cancer treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase